Menu

About Us

Our Mission

Asieris Pharmaceuticals is committed to leading the development of new drugs for the treatment of genitourinary tumors and other related diseases.

Our Values

Responsibility. Respect. Innovation. Excellence.

Timeline

2010
  • Asieris Pharmaceuticals was founded
 
2011-2015
  • APL-1202 approved by NMPA for innovative drug clinical trial
  • Completed Series A financing
  • APL-1202 China Phase II clinical trial enrollment completed
2016-2017
  • Invited to European Association of Urology Conference to present interim results from the APL-1202 Phase II clinical trial
  • Opened the Shanghai Office
  • Reached agreement with NMPA on the APL-1202 pivotal trial protocol
  • Launched the APL-1202 pivotal trial
2018
  • Opened the Shanghai R&D Center and launched the new Drug R&D Discovery Platform
  • Obtained the US IND for the combination of Asieris' APL-1202 and BeiGene's Tislelizumab as a neoadjuvant therapy for MIBC
  • Opened Beijing Office
  • Completed Series B financing
2019
  • APL-1202 China Phase III clinical trial enrollment completed
  • Signed the worldwide development and commercialization licensing agreement of Cevira® with Photocure
2020
  • APL-1702 received NMPA approval for the international multi-center Phase III clinical trial
  • Submitted the clinical registration application for APL-1202 as a first-line NMIBC treatment
  • APL-1501 approved for Phase I clinical trial in Australia
  • Completed Series C+ & D financing
2021
  • Entered strategic collaboration agreement with Sinopharm, accelerating product commercialization
  • U.S. FDA approved the IND application to investigate the combination of Asieris' APL-1202 and BeiGene's Tislelizumab as a neoadjuvant therapy for MIBC patients
  • CDE approved the IND application to Investigate the combination of Asieris' APL-1202 and BeiGene's Tislelizumab as a neoadjuvant therapy for MIBC patients
  • Bladder cancer diagnosis drug Hexvix® completed its first patient procedure
2022
  • Initial Public Offering (IPO) in Shanghai STAR Market (Stock: 688176.SH)
  • Asieris US R&D Center established, focusing on innovative targets and mechanisms research
Previous slide
Next slide

Management

ESG System

Our philosophy: adhering to our mission of "improving human health and making life more dignified", taking innovative technology as the core driving force, incorporating environment, social responsibility and governance (ESG) into the company's development strategy, and continuously building and improving our ESG management system.
Build an EHS system and continuously optimize management practices.
Protect employees' rights and interests, as well as their physical and mental health.
Focus on corporate governance and protect the rights and interests of our investors.
Actively respond to climate change and reduce our carbon footprint.
Previous slide
Next slide
This site is registered on wpml.org as a development site.